Wyeth Delayed Pondimin Label Revision Pending Redux Review, Plaintiffs Say
Executive Summary
Wyeth-Ayerst stalled a labeling revision for the company's diet drug Pondimin (fenfluramine) until FDA completed its NDA review of the company's related diet drug Redux NDA, plaintiffs' attorneys in the N.J. fen-phen class action suit Vadino, Varalli, and DeBerardinis v. American Home Products maintain.
You may also be interested in...
Wyeth Found No Signal Of Valvular Heart Disease In Diet Drug AEs - Deitch
Wyeth-Ayerst identified no signal of valvular heart disease prior to 1997 in adverse drug event reports submitted for the weight loss agents Pondimin (fenfluramine) and Redux (dexfenfluramine), former Wyeth-Ayerst Senior VP-Medical Affairs Marc Deitch, MD, testified in the New Jersey diet drug class action suit.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials